Voices
From Grant to Phase 3 Success: Advancing Rare Sarcoma Research – Conquer Cancer
Mark Dickson

From Grant to Phase 3 Success: Advancing Rare Sarcoma Research – Conquer Cancer

Conquer Cancer, the ASCO Foundation, shared on LinkedIn:

“Developing therapies for rare diseases requires immense patience and persistence.

In 2011, Dr. Mark Dickson received a Conquer Cancer grant to study a rare sarcoma subtype, liposarcoma. That early investment launched a Phase 2 study of CDK4 inhibition, culminating in the historic Phase 3 SARC041 trial results presented at ASCO’s Annual Meeting.

Learn how early-career research support provides the critical foundation for clinical breakthroughs for rare diseases.”

Conquer Cancer

American Society of Clinical Oncology ASCO ASCO Annual Meeting cancer Cancer research CDK4 inhibition CDK4 inhibitor clinical trials Conquer Cancer drug development liposarcoma Mark Dickson OncoDaily Oncology oncology research phase 2 trial Phase 3 Trial Rare Cancers rare diseases SARC041 sarcoma soft tissue sarcoma the ASCO Foundation translational research